Mast cells: Target and source of neuropeptides

Current Pharmaceutical Design

Volumn 15, Issue 29, 2009, Pages 3433-3445

  Tore, F ^a   Tuncel, N ^b  

^a ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

^b ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Calcitonine gene related peptide; Galanin; Mast cell; Neuromedin U; Neurotensin; Substance p; Urocortin; Vasoactive intestinal peptide

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CATHEPSIN; ENDORPHIN; G PROTEIN COUPLED RECEPTOR KINASE; GALANIN; GELATINASE A; INTERSTITIAL COLLAGENASE; LEUKOTRIENE; NEUROMEDIN U; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROTENSIN; PROSTAGLANDIN D2; SOMATOSTATIN; SUBSTANCE P; TACHYKININ RECEPTOR; THROMBOCYTE ACTIVATING FACTOR; TOLL LIKE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANGIOGENESIS; CELL FUNCTION; CELL MATURATION; CELLULAR DISTRIBUTION; EXTRACELLULAR MATRIX; GENE ACTIVATION; HOMEOSTASIS; HUMAN; INFLAMMATION; MAST CELL; MAST CELL DEGRANULATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; REVIEW; SYNAPTIC TRANSMISSION; WOUND HEALING;

ANIMALS; HUMANS; MAST CELLS; NEUROPEPTIDES; RECEPTORS, CELL SURFACE;

EID: 70449389370     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789105036     Document Type: Review

References (125)

1. Crivellato E, Beltrami C, Mallardi F, Ribatti D. Paul Ehrlich's doctoral thesis: a milestone in the study of mast cells. Br J Haematol 2003; 123(1): 19-21. (Pubitemid 37222753)
2. Krishnaswamy G, Ajitawi O, Chi DS. In: Krishnaswamy G, Chi DS, Eds. Mast cells Methods and protocols. Humana Press Inc.: Totowa, 2006; 315,3-68.
3. Nilsson G, Costa JJ, Metcalfe DD. In: Gallin JI, Snyderman R, Eds, Mast cells and basophils, Lippincott-Raven: Philadelphia 1999; 97-117.
4. Theoharides TC, Kalogeromitros D. The critical role of mast cells in allergy and inflammation. Ann N Y Acad Sci 2006; 1088: 78-99., (Pubitemid 47092046)
5. Galli SJ, Tsai M. Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci 2008; 49(1): 7-19. (Pubitemid 350236713)
6. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997; 77(4): 1033-1079
7. Enerbäck L. Mast cells in rat gastrointestinal mucosa. 3. Reactivity towards compound 48/80. Acta Pathol Microbiol Scand 1966; 66(3): 313-322
8. Tore F, Reynier-Rebuffel AM, Tuncel N, Callebert J, Aubineau P. Effects of sepsis on mast cells in rat dura mater: influence of L-NAME and VIP. Br J Pharmacol 2001; 134(7): 1367-1374 (Pubitemid 33131886)
9. Dimitriadou V, Rouleau A, Trung Tuong MD, Newlands GJ, Miller HR, Luffau G, et al. Functional relationships between sensory nerve fibers and mast cells of dura mater in normal and inflammatory conditions. Neuroscience 1997; 77(3): 829-839 (Pubitemid 27092139)
10. Castells M, Mast cells: molecular and cell biology. J Asthma Allergy Immunol 1999; 1: 1.
11. Gurish MF, Boyce JA. Mast cells: ontogeny, homing, and recruitment of a unique innate effector cell. J Allergy Clin Immunol 2006; 117(6): 1285-1291
12. Balakumar P, Singh AP, Ganti SS, Krishan P, Ramasamy S, Singh M. Resident cardiac mast cells: are they the major culprit in the pathogenesis of cardiac hypertrophy? Basic Clin Pharmacol Toxicol 2008; 102(1): 5-9.
13. Caughey GH. Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev 2007; 217: 141-154
14. Williams CM, Galli SJ. Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J Exp Med 2000; 192(3): 455-462
15. Yu M, Tsai M, Tam SY, Jones C, Zehnder J, Galli SJ. Mast cells can promote the development of multiple features of chronic asthma in mice. J Clin Invest 2006; 116(6): 1633-1641 (Pubitemid 43911017)
16. Gross KJ, Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Inflamm Bowel Dis 2007; 13(7): 918-932 (Pubitemid 47203871)
17. Malaviya R, Ikeda T, Ross E, Abraham SN. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 1996; 381(6577): 77-80. (Pubitemid 26130006)
18. Mallen-St Clair J, Pham CT, Villalta SA, Caughey GH, Wolters PJ. Mast cell dipeptidyl peptidase I mediates survival from sepsis. J Clin Invest 2004; 113(4): 628-634
19. Norrby K. Mast cells and angiogenesis. APMIS 2002; 110(5): 355-371
20. Nakano T, Sonoda T, Hayashi C, Yamatodani A, Kanayama Y, Yamamura T, et al. Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell-deficient W/Wv mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells. J Exp Med 1985; 162(3): 1025-1043 (Pubitemid 16248206)
21. Dvorak AM. Ultrastructural studies of human basophils and mast cells. J Histochem Cytochem 2005; 53(9): 1043-1070 (Pubitemid 41262975)
22. Vliagoftis H, Befus AD Mast cells at mucosal frontiers. Curr Mol Med 2005; 5(6): 573-589 (Pubitemid 41236557)
23. Reid AC, Silver RB, Levi R. Renin: at the heart of the mast cell. Immunol Rev 2007; 217: 123-140
24. Moriyama M, Matsukawa A, Kudoh S, Takahashi T, Sato T, Kano T, et al. The neuropeptide neuromedin U promotes IL-6 production from macrophages and endotoxin shock. Biochem Biophys Res Commun 2006; 341(4): 1149-1154 (Pubitemid 43221785)
25. Slominski A, Zbytek B, Zmijewski M, Slominski RM, Kauser S, Wortsman J, et al. Corticotropin releasing hormone and the skin. Front Biosci 2006; 11: 2230-2248
26. Akaishi S, Ogawa R, Hyakusoku H. Keloid and hypertrophic scar: neurogenic inflammation hypotheses. Med Hypotheses 2008; 71(1): 32-38
27. Hildebrand KA, Zhang M, Hart DA. Joint capsule mast cells and neuropeptides are increased within four weeks of injury and remain elevated in chronic stages of posttraumatic contractures. J Orthop Res 2008; 26(10): 1313-1319
28. Kempuraj D, Papadopoulou NG, Lytinas M, Huang M, Kandere-Grzybowska K, Madhappan B, et al. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology 2004; 145(1): 43-48 (Pubitemid 38094499)
29. Lennerz JK, Rühle V, Ceppa EP, Neuhuber WL, Bunnett NW, Grady EF, et al. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol 2008; 507(3): 1277-1299
30. Luger TA, Lotti T. Neuropeptides: role in inflammatory skin diseases. J Eur Acad Dermatol Venereol 1998; 10(3): 207-211 (Pubitemid 28238505)
31. Groneberg DA, Welker P, Fischer TC, Dinh QT, Grützkau A, Peiser C, et al. Down-regulation of vasoactive intestinal polypeptide receptor expression in atopic dermatitis. J Allergy Clin Immunol 2003; 111(5): 1099-1105 (Pubitemid 36570872)
32. D'Andrea MR, Rogahn CJ, Andrade-Gordon P. Localization of protease-activated receptors-1 and -2 in human mast cells: indications for an amplified mast cell degranulation cascade. Biotech Histochem 2000; 75(2): 85-90. (Pubitemid 30618405)
33. Stenton GR, Nohara O, Déry RE, Vliagoftis H, Gilchrist M, Johri A, et al. Proteinase-activated receptor (PAR)-1 and -2 agonists induce mediator release from mast cells by pathways distinct from PAR-1 and PAR-2. J Pharmacol Exp Ther 2002; 302(2): 466-474 (Pubitemid 34787208)
34. Payne V, Kam PC. Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia 2004; 59(7): 695-703. (Pubitemid 38997011)
35. Sommerhoff CP, Schaschke N. Mast cell tryptase beta as a target in allergic inflammation: an evolving story. Curr Pharm Des 2007; 13(3): 313-332 (Pubitemid 46085281)
36. Alic A, Hashemi-Shirazi N, Pearce FL. Protease activated receptors and mast cell activation. Inflamm Res 2001; 50 (Suppl 2): S57-8. (Pubitemid 32452967)
37. Stelekati E, Orinska Z, Bulfone-Paus S. Mast cells in allergy: innate instructors of adaptive responses. Immunobiology 2007; 212(6): 505-519 (Pubitemid 46825249)
38. Applequist SE, Wallin RP, Ljunggren HG. Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int Immunol 2002; 14(9): 1065-1074
39. McCurdy JD, Lin TJ, Marshall JS. Toll-like receptor 4-mediated activation of murine mast cells. J Leukoc Biol 2001; 70(6): 977-984
40. Supajatura V, Ushio H, Nakao A, Akira S, Okumura K, Ra C, et al. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest 2002; 109(10): 1351-1359 (Pubitemid 34546900)
41. Bischoff SC, Krämer S. Human mast cells, bacteria, and intestinal immunity. Immunol Rev 2007; 217: 329-337 (Pubitemid 46718156)
42. Gomariz RP, Arranz A, Juarranz Y, Gutierrez-Cañas I, Garcia-Gomez M, Leceta J, et al. Regulation of TLR expression, a new perspective for the role of VIP in immunity. Peptides 2007; 28(9): 1825-1832 (Pubitemid 47361437)
43. Bulut K, Felderbauer P, Deters S, Hoeck K, Schmidt-Choudhury A, Schmidt WE, et al. Sensory neuropeptides and epithelial cell restitution: the relevance of SP- and CGRP-stimulated mast cells. Int J Colorectal Dis 2008; 23(5): 535-541
44. Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 2008; 123(3): 398-410. (Pubitemid 351171192)
45. Talero E, Sánchez-Fidalgo S, Calvo JR, Motilva V. Chronic administration of galanin attenuates the TNBS-induced colitis in rats. Regul Pept 2007; 141(1-3): 96-104. (Pubitemid 46482689)
46. Tatemoto K, Nozaki Y, Tsuda R, Konno S, Tomura K, Furuno M, et al. Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors. Biochem Biophys Res Commun 2006; 349(4): 1322-1328 (Pubitemid 44416402)
47. Dong X, Han S, Zylka MJ, Simon MI, Anderson DJ. A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell 2001; 106(5): 619-632 (Pubitemid 32879323)
48. Robas N, Mead E, Fidock M. MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. J Biol Chem 2003; 278(45): 44400-44404 (Pubitemid 37377189)
49. Shanahan F, Denburg JA, Fox J, Bienenstock J, Befus D. Mast cell heterogeneity: effects of neuroenteric peptides on histamine release. J Immunol 1985; 135(2): 1331-1337 (Pubitemid 16237456)
50. Niissalo S, Hukkanen M, Imai S, Törnwall J, Konttinen YT. Neuropeptides in experimental and degenerative arthritis. Ann N Y Acad Sci 2002; 966: 384-399
51. Peters EM, Ericson ME, Hosoi J, Seiffert K, Hordinsky MK, Ansel JC, et al. Neuropeptide control mechanisms in cutaneous biology: physiological and clinical significance. J Invest Dermatol 2006; 126(9): 1937-1947 (Pubitemid 44244839)
52. Lundy FT, Linden GJ. Neuropeptides And Neurogenic Mechanisms In Oral And Periodontal Inflammation. Crit Rev Oral Biol Med 2004; 15(2): 82-98.
53. Bischoff SC, Schwengberg S, Lorentz A, Manns MP, Bektas H, Sann H, et al. Substance P and other neuropeptides do not induce mediator release in isolated human intestinal mast cells. Neurogastroenterol Motil 2004; 16(2): 185-193 (Pubitemid 38580963)
54. Zhang C, McDougall JJ. Stimulation of sensory neuropeptide release by nociceptin/orphanin FQ leads to hyperaemia in acutely inflamed rat knees. Br J Pharmacol 2006; 148(7): 938-946 (Pubitemid 44543611)
55. Saraceno R, Kleyn CE, Terenghi G, Griffiths CE. The role of neuropeptides in psoriasis. Br J Dermatol 2006; 155(5): 876-882
56. Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 2004; 84: 903-934 (Pubitemid 38823770)
57. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. BIBN 4096 BS Clinical Proof of Concept Study Group. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350(11): 1104-1110
58. Durham PL. CGRP-receptor antagonists--a fresh approach to migraine therapy? N Engl J Med 2004; 350(11): 1073-1075
59. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002; 22: 54-61. (Pubitemid 34626025)
60. Steinhoff M, Ständer S, Seeliger S, Ansel JC, Schmelz M, Luger T. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol 2003; 139(11): 1479-1488 (Pubitemid 37433137)
61. Eschenfelder CC, Benrath J, Zimmermann M, Gillardon F. Involvement of substance P in ultraviolet irradiation-induced inflammation in rat skin. Eur J Neurosci 1995; 7(7): 1520-1526
62. Khalil Z, Townley SL, Grimbaldeston MA, Finlay-Jones JJ, Hart PH. cis-Urocanic acid stimulates neuropeptide release from peripheral sensory nerves. J Invest Dermatol 2001; 117(4): 886-891 (Pubitemid 33001207)
63. Ansel JC, Brown JR, Payan DG, Brown MA. Substance P selectively activates TNF-alpha gene expression in murine mast cells. J Immunol 1993; 150(10): 4478-4485
64. Van der Kleij HP, Ma D, Redegeld FA, Kraneveld AD, Nijkamp FP, Bienenstock J. Functional expression of neurokinin 1 receptors on mast cells induced by IL-4 and stem cell factor. J Immunol 2003; 171(4): 2074-2079 (Pubitemid 36966491)
65. Seiffert K, Granstein RD. Neuropeptides and neuroendocrine hormones in ultraviolet radiation-induced immunosuppression. Methods 2002; 28: 97-103.
66. Toyoda M, Nakamura M, Nakada K, Nakagawa H, Morohashi M. Characteristic alterations of cutaneous neurogenic factors in photoaged skin. Br J Dermatol 2005; 153 Suppl 2: 13-22. (Pubitemid 41784068)
67. Townley SL, Grimbaldeston MA, Ferguson I, Rush RA, Zhang SH, Zhou XF, et al. Nerve growth factor, neuropeptides, and mast cells in ultraviolet-B-induced systemic suppression of contact hypersensitivity responses in mice. J Invest Dermatol 2002; 118(3): 396-401. (Pubitemid 34227154)
68. Xiang Z, Nilsson G. IgE receptor-mediated release of nerve growth factor by mast cells. Clin Exp Allergy 2000; 30(10): 1379-1386 (Pubitemid 30765645)
69. Aloe L, Bracci-Laudiero L, Bonini S, Manni L. The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases. Allergy 1997; 52(9): 883-894 (Pubitemid 27375005)
70. Johnson D, Lanahan A, Buck CR, Sehgal A, Morgan C, Mercer E, et al. Expression and structure of the human NGF receptor. Cell 1986; 47(4): 545-554 (Pubitemid 17215345)
71. Lindsay RM, Harmar AJ. Nerve growth factor regulates expression of neuropeptide genes in adult sensory neurons. Nature 1989; 337(6205): 362-364
72. Nilsson G, Alving K, Ahlstedt S, Hökfelt T, Lundberg JM. Peptidergic innervation of rat lymphoid tissue and lung: relation to mast cells and sensitivity to capsaicin and immunization. Cell Tissue Res 1990; 262(1): 125-133 (Pubitemid 20308108)
73. Fischer A, McGregor GP, Saria A, Philippin B, Kummer W. Induction of tachykinin gene and peptide expression in guinea pig nodose primary afferent neurons by allergic airway inflammation. J Clin Invest 1996; 98(10): 2284-2291 (Pubitemid 26394202)
74. McDougall JJ, Barin AK. The role of joint nerves and mast cells in the alteration of vasoactive intestinal peptide (VIP) sensitivity during inflammation progression in rats. Br J Pharmacol 2005; 145(1): 104-113
75. Nigrovic PA, Lee DM. Synovial mast cells: role in acute and chronic arthritis. Immunol Rev 2007; 217: 19-37.
76. Gruber B, Poznansky M, Boss E, Partin J, Gorevic P, Kaplan AP. Characterization and functional studies of rheumatoid synovial mast cells. Activation by secretagogues, anti-IgE, and a histamine-releasing lymphokine. Arthritis Rheum 1986; 29(8): 944-955
77. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002; 297(5587): 1689-1692 (Pubitemid 35000781)
78. McDougall JJ. Arthritis and pain. Neurogenic origin of joint pain. Arthritis Res Ther 2006; 8(6): 220.
79. Batbayar B, Zelles T, Vér A, Fehér E. Plasticity of the different neuropeptide-containing nerve fibres in the tongue of the diabetic rat. J Peripher Nerv Syst 2004; 9(4): 215-223 (Pubitemid 40105280)
80. Karanth SS, Springall DR, Francavilla S, Mirrlees DJ, Polak JM. Early increase in CGRP- and VIP-immunoreactive nerves in the skin of streptozotocin-induced diabetic rats. Histochemistry 1990; 94(6): 659-666
81. Li ZS, Dong WZ, Zou DW, Zou XP, Xu GM, Zhu AY, et al. Mast cells and neuropeptidergic terminals: Experimental studies of the mechanism of visceral hypersensitivity in irritable bowel syndrome. Chi J Dig Dis 2003; 4; 111-117
82. Barbara G, Stanghellini V, De Giorgio R, Corinaldesi R. Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil 2006; 18(1): 6-17.
83. Santos J, Perdue MH. Stress and neuroimmune regulation of gut mucosal function. Gut 2000; 47 (Suppl 4): 49-51.
84. Pothoulakis C, Castagliuolo I, LaMont JT. Nerves and intestinal mast cells modulate responses to enterotoxins. News Physiol Sci 1998; 13: 58-63. (Pubitemid 128448393)
85. Anselmi L, Lakhter A, Hirano AA, Tonini M, Sternini C. Expression of galanin receptor messenger RNAs in different regions of the rat gastrointestinal tract. Peptides 2005; 26(5): 815-819 (Pubitemid 40461662)
86. Branchek TA, Smith KE, Gerald C, Walker MW. Galanin receptor subtypes. Trends Pharmacol Sci 2000; 21(3): 109-117
87. Benya RV, Marrero JA, Ostrovskiy DA, Koutsouris A, Hecht G. Human colonic epithelial cells express galanin-1 receptors, which when activated cause Cl- secretion. Am J Physiol 1999; 276: G64-72. (Pubitemid 29063601)
88. Howard AD, Wang R, Pong SS, Mellin TN, Strack A, Guan XM 19. Identification of receptors for neuromedin U and its role in feeding. Nature 2000; 406(6791): 70-74
89. Moriyama M, Furue H, Katafuchi T, Teranishi H, Sato T, Kano T, Kojima M, Yoshimura M. Presynaptic modulation by neuromedin U of sensory synaptic transmission in rat spinal dorsal horn neurones. J Physiol 2004; 559(3): 707-713 (Pubitemid 39276161)
90. Brighton PJ, Szekeres PG, Wise A, Willars GB. Signaling and ligand binding by recombinant neuromedin U receptors: evidence for dual coupling to Galphaq/11 and Galphai and an irreversible ligand-receptor interaction. Mol Pharmacol 2004; 66(6): 1544-1556 (Pubitemid 39564781)
91. Hedrick JA, Morse K, Shan L, Qiao X, Pang L, Wang S, et al.. Identification of a human gastrointestinal tract and immune system receptor for the peptide neuromedin U. Mol Pharmacol 2000; 58(4): 870-875
92. Moriyama M, Sato T, Inoue H, Fukuyama S, Teranishi H, Kangawa K, et al. The neuropeptide neuromedin U promotes inflammation by direct activation of mast cells. J Exp Med 200518; 202(2): 217-224
93. Piliponsky AM, Chen CC, Nishimura T, Metz M, Rios EJ, Dobner PR, et al. Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis. Nat Med 2008; 14(4): 392-398
94. Paus R, Theoharides TC, Arck PC. Neuroimmunoendocrine circuitry of the 'brain-skin connection'. Trends Immunol 2006; 27(1): 32-39
95. Maeno H, Yamada K, Santo-Yamada Y, Aoki K, Sun YJ, Sato E, et al. Comparison of mice deficient in the high- or low-affinity neurotensin receptors, Ntsr1 or Ntsr2, reveals a novel function for Ntsr2 in thermal nociception. Brain Res 2004; 998(1): 122-129 (Pubitemid 38077132)
96. Theoharides TC, Donelan JM, Papadopoulou N, Cao J, Kempuraj D, Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci 2004; 25(11): 563-568 (Pubitemid 39371146)
97. Alexacos N, Pang X, Boucher W, Cochrane DE, Sant GR, Theoharides TC. Neurotensin mediates rat bladder mast cell degranulation triggered by acute psychological stress. Urology 1999; 53(5): 1035-1040 (Pubitemid 29196325)
98. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E, et al. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 1998; 139(1): 403-413 (Pubitemid 28166335)
99. Kempuraj D, Papadopoulou N, Stanford EJ, Christodoulou S, Madhappan B, Sant GR, et al. Increased numbers of activated mast cells in endometriosis lesions positive for corticotropin-releasing hormone and urocortin. Am J Reprod Immunol 2004; 52(4): 267-275 (Pubitemid 39462197)
100. Wu Y, Hu J, Zhang R, Zhou C, Xu Y, Guan X, Li S.Enhanced intracellular calcium induced by urocortin is involved in degranulation of rat lung mast cells. Cell Physiol Biochem 2008; 21(1-3): 173-182
101. Wu Y, Xu Y, Zhou H, Tao J, Li S. Expression of urocortin in rat lung and its effect on pulmonary vascular permeability. J Endocrinol 2006; 189(1): 167-178 (Pubitemid 43670711)
102. Said SI, Mutt V. Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon. Eur J Biochem 1972; 28(2): 199-204.
103. Said SI, Dickman KG. Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide. Regul Pept 2000; 93(1-3): 21-29 (Pubitemid 30738402)
104. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, et al International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 1998; 50(2): 265-270
105. Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M. Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des 2001; 7(2): 89-111. (Pubitemid 32409709)
106. Said SI, Berisha HI, Pakbaz H. N-methyl-D-aspartate receptors outside the central nervous system: activation causes acute lung injury that is mediated by nitric oxide synthesis and prevented by vasoactive intestinal peptide. Neuroscience 1995; 65(4): 943-946
107. Tunçel N, Töre F, Sahintürk V, Ak D, Tunçel M. Vasoactive intestinal peptide inhibits degranulation and changes granular content of mast cells: a potential therapeutic strategy in controlling septic shock. Peptides 2000; 21(1): 81-89 (Pubitemid 30126046)
108. Tunçel N, Töre FC. The effect of vasoactive intestinal peptide (VIP) and inhibition of nitric oxide synthase on survival rate in rats exposed to endotoxin shock. Ann N Y Acad Sci 1998; 865: 586-589
109. Erden SH, Tunçel N, Aydin Y, Sahintürk V, Koşar M, Tunçel M. The effect of vasoactive intestinal peptide (VIP) and inhibition of nitric oxide on renal tissue injury of rats exposed to hemorrhagic ischemia and retransfusion: a possible interaction mechanism among mast cells and tissue histamine. Ann N Y Acad Sci 1998; 865: 570-581 (Pubitemid 29047888)
110. Tunçel N, Erkasap N, Sahintürk V, Ak DD, Tunçel M. The protective effect of vasoactive intestinal peptide (VIP) on stress-induced gastric ulceration in rats. Ann N Y Acad Sci 1998; 865: 309-322 (Pubitemid 29047840)
111. Tikiz H, Tunçel N, Gürer F, Baycu C. Mast cell degranulation in hemorrhagic shock in rats and the effects of vasoactive intestinal peptide, aprotinin and H1 and H2-receptor blockers on degranulation. Pharmacology 1991; 43(1): 47-52.
112. Tikiz H, Tunçel N, Akin MZ, Gürer F. The effect of vasoactive intestinal peptide (VIP) and naloxone combination on survival rates in rats exposed to severe hemorrhage. Peptides 1992; 13(1): 83-89
113. Tunçel N, Gürer F, Aral E, Uzuner K, Aydin Y, Bayçu C. The effect of vasoactive intestinal peptide (VIP) on mast cell invasion/degranulation in testicular interstitium of immobilized + cold stressed and beta-endorphin-treated rats. Peptides 1996; 17(5): 817-824 (Pubitemid 26258611)
114. Can C, Töre F, Tunçel N, Uysal O, Gürer F, Ak D, et al. Protective effect of vasoactive intestinal peptide on testicular torsion-detorsion injury: association with heparin-containing mast cells. Urology 2004; 63(1): 195-200. (Pubitemid 38147592)
115. Tunçel N, Sener E, Cerit C, Karasu U, Gürer F, Sahintürk V, et al. Brain mast cells and therapeutic potential of vasoactive intestinal peptide in a Parkinson's disease model in rats: brain microdialysis, behavior, and microscopy. Peptides 2005; 26(5): 827-836 (Pubitemid 40461664)
116. El-Shazly A, Berger P, Girodet PO, Ousova O, Fayon M, Vernejoux JM, et al. Fraktalkine produced by airway smooth muscle cells contributes to mast cell recruitment in asthma. J Immunol 2006; 176(3): 1860-1868 (Pubitemid 43134331)
117. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002; 346(22): 1699-1705 (Pubitemid 34547483)
118. Chanez P, Springall D, Vignola AM, Moradoghi-Hattvani A, Polak JM, Godard P, Bousquet J. Bronchial mucosal immunoreactivity of sensory neuropeptides in severe airway diseases. Am J Respir Crit Care Med 1998; 158(3): 985-990 (Pubitemid 28449470)
119. Bellinger DL, Lorton D, Brouxhon S, Felten S, Felten DL. The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv Neuroimmunol 1996; 6(1): 5-27. (Pubitemid 26185008)
120. Tam EK, Caughey GH. Degradation of airway neuropeptides by human lung tryptase. Am J Respir Cell Mol Biol 1990; 3(1): 27-32.
121. Franconi GM, Graf PD, Lazarus SC, Nadel JA, Caughey GH. Mast cell tryptase and chymase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the ferret. J Pharmacol Exp Ther 1989; 248(3): 947-951
122. Mellon MB, Frank BT, Fang KC. Mast cell alpha-chymase reduces IgE recognition of birch pollen profilin by cleaving antibody-binding epitopes. J Immunol 2002; 168(1): 290-297
123. Christmas D, Hood S, Nutt D. Potential novel anxiolytic drugs. Curr Pharm Des 2008; 14(33): 3534-3546
124. Ebner K, Sartori SB, Singewald N. Tachykinin receptors as therapeutic targets in stress-related disorders. Curr Pharm Des 2009; 15(14): 1647-1674
125. Greenfield JR, Campbell LV. Role of the autonomic nervous system and neuropeptides in the development of obesity in humans: targets for therapy? Curr Pharm Des 2008; 14(18): 1815-1820